In addition, researchers are actively developing glucose‐responsive “smart” insulins designed to activate only when blood glucose exceeds physiological thresholds, potentially revolutionizing diabetes treatment through the replacement of more physiological insulin. This evidence concerns the gene INS and diabetes mellitus.